【誤】【２】06/17/2018
Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma
【正】
06/15/2018
China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC)
asa*****
>>485
【誤】【２】06/17/2018
Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma
【正】
06/15/2018
China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC)
大変な正誤をお詫び申し上げます、但し、操作は同じです。
申し訳ございませんでした。お許しください。